W W IsHak1, J Mirocha, D James, G Tobia, J Vilhauer, H Fakhry, S Pi, E Hanson, R Nashawati, E D Peselow, R M Cohen. 1. Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Abstract
OBJECTIVE: This study examines the impact of major depressive disorder (MDD) and its treatment on quality of life (QOL). METHOD: From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we analyzed complete data of 2280 adult MDD out-patients at entry/exit of each level of antidepressant treatments and after 12 months of entry to follow-up. QOL was measured using the QOL Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The proportions of patients scoring 'within-normal' QOL (within 10% of Q-LES-Q community norms) and those with 'severely impaired' QOL (>2 SD below Q-LES-Q community norms) were analyzed. RESULTS: Before treatment, no more than 3% of MDD patients experienced 'within-normal' QOL. Following treatment, statistically significant improvements were detected; however, the proportion of patients achieving 'within-normal' QOL did not exceed 30%, with >50% of patients experiencing 'severely impaired' QOL. Although remitted patients had greater improvements compared with non-remitters, 32-60% continued to experience reduced QOL. 12-month follow-up data revealed that the proportion of patients experiencing 'within-normal' QOL show a statistically significant decrease in non-remitters. CONCLUSION: Symptom-focused treatments of MDD may leave a misleading impression that patients have recovered when, in fact, they may be experiencing ongoing QOL deficits. These findings point to the need for investigating specific interventions to ameliorate QOL in MDD.
RCT Entities:
OBJECTIVE: This study examines the impact of major depressive disorder (MDD) and its treatment on quality of life (QOL). METHOD: From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we analyzed complete data of 2280 adult MDD out-patients at entry/exit of each level of antidepressant treatments and after 12 months of entry to follow-up. QOL was measured using the QOL Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The proportions of patients scoring 'within-normal' QOL (within 10% of Q-LES-Q community norms) and those with 'severely impaired' QOL (>2 SD below Q-LES-Q community norms) were analyzed. RESULTS: Before treatment, no more than 3% of MDDpatients experienced 'within-normal' QOL. Following treatment, statistically significant improvements were detected; however, the proportion of patients achieving 'within-normal' QOL did not exceed 30%, with >50% of patients experiencing 'severely impaired' QOL. Although remitted patients had greater improvements compared with non-remitters, 32-60% continued to experience reduced QOL. 12-month follow-up data revealed that the proportion of patients experiencing 'within-normal' QOL show a statistically significant decrease in non-remitters. CONCLUSION: Symptom-focused treatments of MDD may leave a misleading impression that patients have recovered when, in fact, they may be experiencing ongoing QOL deficits. These findings point to the need for investigating specific interventions to ameliorate QOL in MDD.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Diane Warden; William McKinney; Michael Downing; Susan R Berman; Amy Farabaugh; James F Luther; Andrew A Nierenberg; Judith A Callan; Harold A Sackeim Journal: J Clin Psychiatry Date: 2006-02 Impact factor: 4.384
Authors: Waguih William Ishak; Konstantin Balayan; Catherine Bresee; Jared Matt Greenberg; Hala Fakhry; Scott Christensen; Mark Hyman Rapaport Journal: Qual Life Res Date: 2012-04-29 Impact factor: 4.147
Authors: L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller Journal: J Affect Disord Date: 1998-09 Impact factor: 4.839
Authors: Kathleen S Bingham; Ellen M Whyte; Benoit H Mulsant; Anthony J Rothschild; Matthew V Rudorfer; Patricia Marino; Samprit Banerjee; Meryl A Butters; George S Alexopoulos; Barnett S Meyers; Alastair J Flint Journal: J Affect Disord Date: 2019-05-28 Impact factor: 4.839
Authors: Emma Morton; Erin E Michalak; Anthony Levitt; Robert D Levitan; Amy Cheung; Rachel Morehouse; Rajamannar Ramasubbu; Lakshmi N Yatham; Edwin M Tam; Raymond W Lam Journal: Can J Psychiatry Date: 2020-06-23 Impact factor: 4.356
Authors: Waguih William IsHak; Alexander J Steiner; Anna Klimowicz; Kaitlyn Kauzor; Jonathan Dang; Brigitte Vanle; Christina Elzahaby; Mark Reid; Lekeisha Sumner; Itai Danovitch Journal: Psychopharmacol Bull Date: 2018-01-15
Authors: Emma Morton; Venkat Bhat; Peter Giacobbe; Wendy Lou; Erin E Michalak; Shane McInerney; Trisha Chakrabarty; Benicio N Frey; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam Journal: CNS Drugs Date: 2021-04-16 Impact factor: 5.749
Authors: Faiza Siddiqui; Marija Barbateskovic; Sophie Juul; Kiran Kumar Katakam; Klaus Munkholm; Christian Gluud; Janus Christian Jakobsen Journal: Syst Rev Date: 2021-06-09
Authors: Heidemarie Lex; Steven W Nevers; Erica L Jensen; Yarden Ginsburg; Daniel F Maixner; Brian J Mickey Journal: J Affect Disord Date: 2021-05-18 Impact factor: 6.533